jupiterneurosciences.com (JUNS) - Price-to-Projected Revenue Ratio
The projected market cap-to-revenue ratio for Jupiter Neurosciences Inc (JUNS) exhibits volatility, as the business relies on secondary offerings due to a lack of commercial products. Growth potential is driven by AI-powered robotic laboratories for data analysis and a team of high-paid neuroinflammation experts. The value of 41.20 characterizes this valuation metric, indicating the issuer's current stage of development.
Comprehensive metric breakdowns and analytics for jupiterneurosciences.com (JUNS)
- stock price and consensus target price:
- market capitalization indicators:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Jupiter Neurosciences|JUNS - Company Cumulative Debt|Debt to Book Capitalization Ratio Jupiter Neurosciences Inc|JUNS - Long-Term Debt Volume|Company Short-Term Debts Jupiter Neurosciences|Quick Ratio jupiterneurosciences.com
- financial results and valuation multiples details:
JUNS - Net Financial Result|Projected Future Earnings Jupiter Neurosciences Inc|JUNS - Market Cap to Earnings|Future Price to Earnings Jupiter Neurosciences Inc|JUNS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Jupiter Neurosciences Inc|JUNS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Jupiter Neurosciences|JUNS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months jupiterneurosciences.com|JUNS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Jupiter Neurosciences Inc
- revenue and sales details:
Initial company analysis:JUNS (Jupiter Neurosciences Inc)
The forward P/S ratio determines the market value of a business relative to expected sales volume, allowing for an assessment of the premium investors are willing to pay for future cash flows. By analyzing the projected P/S parameter, one can compare the capitalization rates of Jupiter Neurosciences Inc (JUNS) with the commercialization potential of their neurobiological developments aimed at protecting neurons in Alzheimer's and Parkinson's diseases.
Analysis of competing companies
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|RGC - Price-to-Projected Revenue Ratio|AXSM (Axsome Corp) - Market Cap to Projected Revenue|ACAD: Forward P/S Multiple|Market Cap to Future Revenue Ratio xenon-pharma.com (XENE)|Forward Price-to-Revenue Multiple VKTX|Forward P/S Multiple Supernus Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Harmony Biosciences HRMY|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|PRAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Prothena Corporation (PRTA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALEC|ANNX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Omeros OMER|NGNE: Market Cap to Projected Revenue|AC Immune - Forward P/S Multiple|voyagertherapeutics.com (VYGR) - Forward Price-to-Revenue Multiple|NMRA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CGTX (Cognition Therapeutics)|IKT (inhibikase.com) - Forward Price to Sales|Forward P/S Multiple SAVA (Cassava Sciences)|Market Cap to Expected Sales Ratio Assertio Holdings (ASRT)|COYA - Price-to-Projected Revenue Ratio|VTGN (Vistagen Therapeutics) - Market Cap to Projected Revenue|OVID: Forward P/S Multiple|Forward Price-to-Revenue Multiple acumenpharm.com|Price-to-Projected Revenue Ratio CervoMed|ATHE (Alterity Therapeutics Ltd) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|Forward P/S Multiple pepgen.com (PEPG)|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Projected Revenue|GRCE - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Firefly Neuroscience, Inc. AIFF|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NRSN|RVPH (Reviva Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Forward Price-to-Revenue Multiple NRXS (NeurAxis)|Forward P/S Multiple heliusmedical.com (HSDT)|Price-to-Projected Revenue Ratio Passage Bio PASG|Forward Price to Sales NEUP|NERV - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|ALZN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple CYCN|Forward P/S Multiple Protagenic|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT: Future Price to Revenue|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Brainstorm Cell Therapeutics Inc. (BCLI)|CARA: Forward Price-to-Revenue Multiple|Chromocell - Price to Expected Revenue Ratio|ELYM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|MRNS: Forward Price to Sales|Forward Price-to-Revenue Multiple NKGN (NKGen)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX: Market Cap to Projected Revenue|Trevena - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vigil Neuroscience|WENA (Anew Medical) - Forward Price-to-Revenue Multiple|Cerevel Corp (CERE) - Forward P/S Multiple
